|
||||||||||||||||||||||
|
|
Alternate Title Phase IV Study of the Relationship Between Residual Platinum Levels in the Blood and Persistent Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
Trial Description Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably. This phase IV trial is studying the relationship between platinum levels in the blood and neurotoxicity in patients who are receiving oxaliplatin for gastrointestinal cancer. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will receive a 2-hour infusion of oxaliplatin. Treatment may repeat every 2-3 weeks for as long as benefit is shown. Patients will also undergo neurological exams and blood collection before beginning treatment, after each course of oxaliplatin, and after finishing treatment. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations GERCOR Groupe Cooperateur Multidisciplinaire en Oncologie
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |